Blood Type Predictor

Blood type is determined by genes inherited from both parents following Mendelian genetics. The ABO system involves three alleles: A, B, and O, where A and B are codominant (both express when present together), while O is recessive (only expresses when two O alleles are present). Each person inherits one allele from each parent, creating six possible genotypes: AA or AO (Type A blood), BB or BO (Type B), AB (Type AB), and OO (Type O). For example, if one parent is Type A (genotype AO) and the other is Type B (genotype BO), their children could be: 25% Type AB (AB genotype), 25% Type A (AO), 25% Type B (BO), or 25% Type O (OO)—the only parent combination that can produce all four blood types. The Rh factor is inherited separately, with positive (+) being dominant over negative (-). Genotypes are ++ or +- (Rh positive) and -- (Rh negative). If both parents are Type O Rh+, children can only be Type O, but could be Rh+ (75% probability) or Rh- (25% probability if both parents carry the recessive - allele). Important impossibilities: Two Type O parents cannot have Type A, B, or AB children; Two Rh- parents cannot have Rh+ children; Type AB parent cannot have Type O child unless rare genetic anomalies (cis-AB or Bombay phenotype) are present.

Blood type calculators provide probabilities, not certainties, and have significant limitations: They show possible blood types and their likelihood but cannot definitively predict which type a specific child will have unless genetics allow only one possibility. For example, two Type O parents can only have Type O children (100% certain), while a Type A (AO) and Type B (BO) parent have 25% chance each for Types A, B, AB, or O—the calculator shows possibilities but cannot predict the actual outcome. Paternity testing limitations: Blood types can exclude paternity but cannot prove it. If a Type O mother has a Type AB child, a man with Type O or Type A (genotype AA) can be definitively excluded as the father because he cannot provide the necessary B allele. However, if that child's blood type is Type A, a Type A man could be the father, but so could millions of other Type A or AB men—blood type alone cannot confirm paternity. DNA testing is required for positive identification (99.99% accuracy). Rare exceptions causing errors: Bombay phenotype (1 in 10,000 in India, 1 in 1,000,000 elsewhere) lacks H antigen, so people with A or B genes phenotypically test as Type O; cis-AB where both A and B are on the same chromosome, allowing two AB parents to have an O child; Chimerism from absorbed twin or maternal cells; Weak A or B antigens may be missed in typing. These rare situations (affecting <0.1% of population) can make calculator predictions appear incorrect. Always use professional blood typing and DNA testing for medical or legal purposes.

Blood type frequencies vary dramatically across populations due to evolutionary pressures and genetic drift: Global averages: Type O (46%), Type A (40%), Type B (10%), Type AB (4%), Rh+ (85%), Rh- (15%). However, ethnic variations are striking: Caucasians (European descent): Type O (45%), A (40%), B (11%), AB (4%); Rh- frequency 15-17%, highest in Basque people (25-30%). African Americans: Type O (51%), A (26%), B (19%), AB (4%); Rh- only 7-8%, much lower than European descent. Hispanics: Type O (57%), A (31%), B (10%), AB (2%); Rh- 8-10%. Asians: Higher Type B frequency (25-30%); Type O (40-43%), A (27-28%), AB (5-7%); Rh- extremely rare (0.1-0.3% in East Asians). Native Americans: Nearly 100% Type O in some populations (e.g., 97-100% in some South American tribes), virtually no Type B, Rh- very rare. Evolutionary theories: Type O may have provided resistance to severe malaria (P. falciparum), explaining high prevalence in malaria-endemic regions. Type A may correlate with plague survival in European populations. Type B is most common along ancient Silk Road trade routes in Asia. Practical implications: For example, a Korean couple (likely Type A, B, or AB) is statistically unlikely to both be Type O, while a Peruvian couple has high probability. These population frequencies affect blood bank inventory needs—Asian blood banks stock minimal Rh- blood, while European banks maintain 15-17% Rh- inventory.

Rh incompatibility is the most clinically significant blood type issue in pregnancy, occurring when an Rh- mother carries an Rh+ fetus (father is Rh+). During pregnancy or delivery, fetal Rh+ blood cells can enter maternal circulation, triggering the mother's immune system to produce anti-Rh antibodies. This rarely affects the first pregnancy, but in subsequent Rh+ pregnancies, maternal antibodies cross the placenta and attack fetal red blood cells, causing hemolytic disease of the newborn (HDN) with severe anemia, jaundice, brain damage, or fetal death. Frequency: Affects approximately 1 in 1,000 births. Without prevention, 16% of Rh- women carrying Rh+ babies develop antibodies. Prevention with RhoGAM: Rh- mothers receive Rh immune globulin (RhoGAM) at 28 weeks gestation and within 72 hours after delivery (if baby is Rh+), preventing antibody formation in 99% of cases. RhoGAM works by destroying any fetal Rh+ cells before the maternal immune system recognizes them. For example, an Rh- woman (genotype --) with an Rh+ partner (genotype ++ or +-) has 50-100% chance of Rh+ baby requiring RhoGAM. ABO incompatibility: Less serious but more common—occurs when mother is Type O and baby is Type A or B. Maternal anti-A or anti-B antibodies can cause mild jaundice in 20-25% of incompatible newborns, but rarely requires treatment beyond phototherapy. Unlike Rh disease, ABO incompatibility can affect first pregnancy and doesn't worsen with subsequent pregnancies. Screening: All pregnant women receive blood typing at first prenatal visit. Rh- women get antibody screening at 28 weeks and delivery. If antibodies are detected, pregnancies require close monitoring with ultrasounds and possible intrauterine transfusions.

While ABO and Rh are most clinically important, over 300 blood group antigens exist across 36 recognized blood group systems: Kell system: Second most important after Rh in transfusion reactions and HDN. Kell antigens (K, k, Kp) can cause severe hemolytic disease. Anti-Kell antibodies develop in 5-10% of K-negative patients receiving K-positive blood. Duffy system (Fy): Critical for Plasmodium vivax malaria—Duffy-negative individuals (Fy-Fy-, found in 70% of West Africans, 0-1% of Caucasians) are completely resistant to vivax malaria because the parasite cannot enter red blood cells. This demonstrates how blood types evolved under disease pressure. Kidd system (Jk): Associated with delayed transfusion reactions. Anti-Jk antibodies decline to undetectable levels between transfusions, then cause hemolysis when patient receives incompatible blood again. MNS system: Includes 46 antigens; rarely causes clinical problems but important in paternity testing and population genetics. Lewis system (Le): Unique because antigens are absorbed onto red cells from plasma rather than synthesized by the cells—affected by secretor status (ability to secrete ABO antigens in body fluids). 20% of Caucasians, 30% of African Americans are non-secretors. Diego system: Almost exclusive to Asian and Native American populations—useful in anthropological studies. Clinical relevance: Patients requiring frequent transfusions (sickle cell disease, thalassemia) often develop alloantibodies to minor blood group antigens, requiring increasingly specific blood matching beyond ABO/Rh. Extended phenotype matching for Kell, Duffy, Kidd, and others reduces alloimmunization risk by 70-90%. This is why comprehensive typing matters for chronically transfused patients, not just ABO/Rh compatibility.

Research demonstrates legitimate associations between blood type and certain health risks, though blood type diets lack scientific support: Cardiovascular disease: Type O has 15-20% lower risk of coronary artery disease and heart attack compared to non-O types. Type AB and Type B have highest risk, with 20-40% increased coronary disease risk in some studies, possibly due to higher cholesterol and von Willebrand factor levels affecting blood clotting. Blood clots (VTE): Type O has 30-40% lower risk of deep vein thrombosis and pulmonary embolism versus non-O types. Type AB has highest risk, approximately 2-fold increase, due to higher factor VIII and von Willebrand factor. Cancer: Type A associated with 20% higher gastric cancer risk, especially in H. pylori infection. Type O has moderately reduced pancreatic cancer risk (15-20% lower). Type A has 12% higher ovarian cancer risk. Infectious diseases: Type O more susceptible to severe cholera and plague. Type A more susceptible to smallpox. Type O has increased severe malaria risk (cerebral malaria), while Duffy-negative protects against vivax malaria. Type O has higher Norwalk virus infection rates. COVID-19: Meta-analyses show Type O has 10-15% reduced infection risk and 13-25% lower risk of severe disease/death, while Type A has modestly increased risk. Blood type diets (D'Adamo): Lack scientific evidence—claims that Type O should eat high-protein (meat-based) diet, Type A vegetarian, etc., are not supported by controlled trials. A 2013 study of 1,455 participants found no health benefits from following blood type-specific diets. Practical implications: While blood type modestly influences disease risk (10-40% relative risk changes), absolute risks remain low and other factors (smoking, diet, exercise, genetics) far outweigh blood type effects. Maintain healthy lifestyle regardless of blood type.